ERK2/p38α MAPK-IN-1

• UNSPSC Description:

  ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC50 of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes[1].

• Target Antigen:

  ERK; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/erk2-p38α-mapk-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=C(OC)C=C(N=C(NC(C2=CSC(COC3=CC=C(F)C=C3)=N2)=O)S4)C4=C1

• Molecular Weight:

  445.49

• References & Citations:

  [1]Hasegawa S, et al. Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or p38α MAPK selectivity. Biochem Biophys Res Commun. 2024 Apr 16;704:149707.|[2]Kinoshita T, et al. Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay. Bioorg Med Chem Lett. 2016 Feb 1;26(3):955-958.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1016427-72-7